NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
12/03/2026
Voltar para busca
Dado oficial do USPTO
BIONTECH
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
BIONTECH
ST13
US500000087523267Classe
1, 5, 16, 31, 42, 44
Pedido
87523267
Registro
5712036
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
50
Atualização mais recente
31/03/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 16, 31, 42, 44
Data de depósito
11/07/2017
Data de registro
02/04/2019
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
12/03/2026
Última transação
31/03/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
705
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
94
Localização do titular
MAINZ, DE
Examinador
WOOD, CAROLINE
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
B. S. (pessoa física)
BioNTech AG
Representantes
Monica Riva Talley Sterne, Kessler, Goldstein & Fox P.L.L.C.
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 16Classe 31Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Active chemical ingredients for use in manufacture of anti-cancer drugs and vaccines ; Adjuvants for use in manufacture of vaccines; Protein arrays and nucleotide arrays for scientific and medical laboratory use; Nucleic acidsproteins and peptides for laboratory use; Diagnostic preparations for scientific or research use other than for medical purposes; Diagnostic preparations for clinical or medical laboratory use
Classe 5
Pharmaceutical products for the prevention and treatment of cancerinfectious diseasesimmunological diseasesexcept vitamin preparationsmineral food supplementsprobioticsomega 3 preparationsdietetic substances and food supplements for medical and non-medical purposes; Vaccines; Adjuvants for medical purposes except vitamin preparationsmineral food supplementsprobioticsomega 3 preparationsdietetic substances and food supplements for medical and non-medical purposes; Chemical reagents used for medical or veterinary purposes; Biochemical reagents used for medical or veterinary purposes for the treatment of cancertreatment of immunological diseasestreatment of infectious diseases; Macromoleculesnucleic acid sequences and proteinsused for medical and veterinary purposes; cell based immune therapeutics for treatment of cancertreatment of immunological diseasestreatment of infectious diseases
Classe 16
Pharmaceutical information leaflets; Printed pamphletsbrochuresmanualsbooksbookletsleafletsflyersinformational sheets and newsletters for providing medicalpharmaceutical and scientific research information
Classe 31
Transgenic live animals and live plants for research and for the production of pharmaceuticalveterinary and biochemical goods
Classe 42
Medical and scientific research in the field of treatment of immunological diseasescancer treatmenttreatment of infectious diseases ; Providing medical and scientific research informationconsultancyadvisory servicesall in the fields of treatment of immunological diseasescancer treatmenttreatment of infectious diseases; Compiling data for medical and scientific researchclinical trialsdrug admission
Classe 44
Medical servicesproviding therapies for treating cancerinfectious diseases and immunological diseases; Veterinary servicesproviding therapies for treating cancerinfectious diseasesimmunological diseases; Medical and pharmaceutical consultation; Medical diagnostic testingmonitoring and reporting services ; Genetic testing for medical purposes
Publicações
Histórico de despachos e eventos da marca no USPTO.
50 publicações encontradas
C15P
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
12/03/2026
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
11/03/2026
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
27/02/2026
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
27/02/2026
EWOR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
27/02/2026
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
27/02/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
27/02/2026
PR23
POST REGISTRATION ACTION MAILED - SEC. 8 & 15
15/09/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
12/09/2025
E815
TEAS SECTION 8 & 15 RECEIVED
01/05/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
24/02/2025
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
24/02/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
24/02/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
24/02/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
24/02/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
24/02/2025
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
02/04/2024
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
29/01/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
16/08/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
16/08/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
02/04/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
15/01/2019
PUBO
PUBLISHED FOR OPPOSITION
15/01/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
26/12/2018
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
27/11/2018
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
14/11/2018
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
09/11/2018
OTHE
CASE RETURNED TO EXAMINATION
29/10/2018
IUCN
NOTICE OF ALLOWANCE CANCELLED
29/10/2018
PCBG
PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
22/10/2018
APET
ASSIGNED TO PETITION STAFF
15/10/2018
TPAD
TEAS PETITION TO AMEND BASIS RECEIVED
27/09/2018
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
24/07/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
29/05/2018
PUBO
PUBLISHED FOR OPPOSITION
29/05/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/05/2018
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
20/04/2018
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
13/04/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/04/2018
XAEC
EXAMINER'S AMENDMENT ENTERED
19/03/2018
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
19/03/2018
GNEA
EXAMINERS AMENDMENT E-MAILED
19/03/2018
CNEA
EXAMINERS AMENDMENT -WRITTEN
19/03/2018
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
13/10/2017
GNRT
NON-FINAL ACTION E-MAILED
13/10/2017
CNRT
NON-FINAL ACTION WRITTEN
13/10/2017
DOCK
ASSIGNED TO EXAMINER
08/10/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
17/07/2017
NWAP
NEW APPLICATION ENTERED
14/07/2017
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace BIONTECH ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.